Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, acquired Kanyos Bio, Inc. and completed of a USD 40M Series B financing. The Kanyos acquisition adds KAN-101 to the portfolio, an antigen-specific treatment for celiac disease with an investigational new drug (IND). Anokion also completed a USD 40M Series B financing with Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene and select Swiss-based private investors.

VISCHER advised Anokion in this transaction with Matthias Staehelin and Luzius Zumstein (both Corporate) as well as Nadia Tarolli and Adrian Briner (both tax).

Press release